Professor Ellen P. Goodman It’s no surprise that Mark Zuckerberg has called for “updating the rules for the Internet” – he signaled as much last April in his testimony before the U.S. Senate, inclining his head towards the yoke of regulation. But things have changed significantly since then and Zuckerberg has missed his moment to lead on … Continue reading Facebook’s Moment for Thought Leadership on Internet Regulation Has Passed…
Category: Blog
Lastowka Short-Form Writing Competition – SUBMISSIONS DUE 4/15/19
Lastowka Short-Form Writing Competition – SUBMISSIONS DUE 4/15/19 The Rutgers Institute for Information Policy & Law is pleased to announce the Lastowka Short-Form Writing Competition. Open to Rutgers students and recent graduates (class of 2018), the award will be given to an entry of 500-1,500 words on a topic of intellectual property or information policy more broadly. … Continue reading Lastowka Short-Form Writing Competition – SUBMISSIONS DUE 4/15/19…
Prof. Carrier writes article on product hopping
The antitrust analysis of product hopping is nuanced. The conduct, which consists of a drug company’s reformulation of its product and encouragement of doctors to switch prescriptions to the reformulated product, sits at the intersection of antitrust law, patent law, the Hatch-Waxman Act, and state substitution laws, and involves uniquely complicated markets with different buyers … Continue reading Prof. Carrier writes article on product hopping…
Addressing Abusive Citizen Petitions
“Citizen petitions” filed with the FDA are supposed to raise legitimate safety concerns. But my work has shown that nearly all are filed by brand drug firms and that the FDA denies more than 90 percent of them. The FDA has offered draft guidance to address abusive citizen petitions. My comment applauds this attention and … Continue reading Addressing Abusive Citizen Petitions…
Challenging Deceptive Drug Pricing
Consumers rely on listed prices being accurate. Imagine walking into your favorite store, bringing your desired item to the counter, and being told that the price you had to pay had little relation to the listed price. Remarkable as it is, this is commonplace in the pharmaceutical industry. Minnesota Attorney General Lori Swanson recently filed … Continue reading Challenging Deceptive Drug Pricing…